Trials / Terminated
TerminatedNCT00126893
Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
Phase 1 Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (planned)
- Sponsor
- Celgene Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single center Phase 1 study to evaluate the safety, pharmacokinetics and pharmacodynamics of CC-401 in subjects with refractory acute myelogenous leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-401 |
Timeline
- Start date
- 2005-10-01
- Completion
- 2006-09-01
- First posted
- 2005-08-05
- Last updated
- 2007-05-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00126893. Inclusion in this directory is not an endorsement.